Talphera, Inc. remains a clinical-stage biopharmaceutical company focusing on developing nafamostat-based therapies, with its lead candidate Niyad advancing through clinical trials including the NEPHRO CRRT study. The company’s May 2026 10-Q confirms ongoing research activities and effective internal controls but reiterates significant financial constraints that cast doubt on its near-term going concern status. Talphera’s strategic moat derives from proprietary licensing agreements and specialized manufacturing partnerships, although reliance on single-source suppliers in Asia poses operational risks. Near-term growth hinges on key clinical milestones and potential regulatory filings while managing funding needs and supply chain uncertainties.